Friday, December 30, 2016 5:45:32 PM
I hope other investments in 2017 treat HDC shareholders better than HDC has treated us over the years. It's hard to fathom that we would be ending the year with the stock price at .013, particularly with Neo having commercialized the prostate test. This doesn't seem plausible, but HDC has proven that it can do anything to disappoint.
Since the company has indicated that it will run out of money by the end of Q1, it should be interesting to see if they quietly turn out the lights, or issue a less-than-credible announcement about suing Neo for not providing HDC with royalties. In any event, since Neo hasn't issued a press release on a test that they invested handsomely in, my guess is that they came to realize the test isn't going to be a game changer after all.
Recent HDVY News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 09:13:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 07:53:39 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM